159 related articles for article (PubMed ID: 7544302)
1. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
[TBL] [Abstract][Full Text] [Related]
2. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
[TBL] [Abstract][Full Text] [Related]
4. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Riess G
Virology; 1994 May; 200(2):696-701. PubMed ID: 7513921
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
[TBL] [Abstract][Full Text] [Related]
10. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
[TBL] [Abstract][Full Text] [Related]
11. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase.
Dueweke TJ; Kézdy FJ; Waszak GA; Deibel MR; Tarpley WG
J Biol Chem; 1992 Jan; 267(1):27-30. PubMed ID: 1370445
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
13. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
Dueweke TJ; Poppe SM; Romero DL; Swaney SM; So AG; Downey KM; Althaus IW; Reusser F; Busso M; Resnick L
Antimicrob Agents Chemother; 1993 May; 37(5):1127-31. PubMed ID: 7685995
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
16. Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.
Isaka Y; Sato A; Kawauchi S; Suyama A; Miki S; Hayami M; Fujiwara T
Microbiol Immunol; 1998; 42(3):195-202. PubMed ID: 9570285
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
18. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
19. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
20. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV
Arch Virol Suppl; 1994; 9():11-7. PubMed ID: 7518271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
